康泰生物(300601.SZ):新型冠狀病毒滅活疫苗被納入緊急使用
格隆匯5月14日丨康泰生物(300601.SZ)公佈,公司近日收到國務院聯防聯控機制科研攻關組疫苗研發專班的通知,根據《中華人民共和國疫苗管理法》第二十條有關規定,公司研發的新型冠狀病毒滅活疫苗經國家衞生健康委提出建議,國家藥品監督管理局組織論證同意緊急使用。
公司自主研發的新型冠狀病毒滅活疫苗用於預防由新型冠狀病毒感染引起的流行性疾病,屬於預防用生物製品第1.1類。新型冠狀病毒滅活疫苗於2021年2月完成I、II期臨牀試驗。目前,公司已啟動開展新型冠狀病毒滅活疫苗III期臨牀試驗相關工作。
公司新型冠狀病毒滅活疫苗此次納入緊急使用,若後續被國家相關部門規模化採購使用將對公司的經營業績產生積極影響,進一步提高公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.